Black Diamond Therapeutics, Inc.
NASDAQ:BDTX · NASDAQ Global Select
-$0.04 today
Vol 1.91M · Avg 1.31M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $22.4M +132.1% | -$69.7M +15.5% | -$82.4M +9.6% | -$91.2M +27.4% | -$125.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $325.0K -5.2% | $343.0K -21.5% | $437.0K -14.0% | $508.0K +147.8% | $205.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $2.2M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $6.6M -37.6% | $10.6M +10.7% | $9.6M -21.3% | $12.2M -13.1% | $14.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$8.7M -224.2% | -$2.7M -173.0% | $3.7M +137.2% | -$9.9M -241.0% | $7.0M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$3.4M -303.7% | $1.7M +181.9% | $597.0K +126.8% | -$2.2M -242.1% | $1.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$5.3M -21.1% | -$4.4M -241.6% | $3.1M +140.3% | -$7.7M -240.7% | $5.5M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $9.0M +1096.9% | -$905.0K -145.3% | $2.0M -39.1% | $3.3M +63.6% | $2.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $29.6M +147.5% | -$62.3M +6.6% | -$66.7M +21.6% | -$85.1M +15.0% | -$100.1M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | $0 | $0 +100.0% | -$33.0K +82.8% | -$192.0K +92.9% | -$2.7M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $27.0K -71.3% | $94.0K | $0 -100.0% | $9.0K -99.7% | $2.7M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$164.0M -33.5% | -$122.9M -98.5% | -$61.9M -2.9% | -$60.1M -21.5% | -$49.5M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $119.0M -14.8% | $139.8M +78.8% | $78.2M -31.2% | $113.7M -37.8% | $182.8M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $74.0K | $0 -100.0% | $95.0K | $0 +100.0% | -$2.7M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$44.9M -364.6% | $17.0M +3.8% | $16.3M -69.4% | $53.4M -59.1% | $130.6M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | -$146.0K -100.6% | $24.5M -65.9% | $71.8M +40493.2% | $177.0K -75.7% | $729.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $1.1M +1184.1% | $82.0K | $0 | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$146.0K -100.6% | $25.5M -64.5% | $71.9M +40539.5% | $177.0K -75.7% | $729.0K | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$15.4M +22.0% | -$19.8M -191.8% | $21.6M +168.4% | -$31.5M -201.1% | $31.2M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $29.6M +147.5% | -$62.3M +6.7% | -$66.8M +21.7% | -$85.3M +17.1% | -$102.9M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Abeona Therapeutics Inc.
NASDAQ:ABEO
$325.16M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$294.84M
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
$255.65M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$242.78M
Inventiva S.A.
NASDAQ:IVA
$184.28M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$169.86M
Immuneering Corporation
NASDAQ:IMRX
$161.00M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$160.64M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$117.86M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$86.61M
SEC Filings
Recent regulatory filings
No filings found.
Does BDTX generate free cash flow?
Black Diamond Therapeutics, Inc. (BDTX) generated $29.61M of free cash flow in fiscal 2025.
How much operating cash flow does BDTX produce?
Operating cash flow was $29.61M, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.